Literature DB >> 28893793

Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis.

Weizhen Xu1, Michael A DeJesus2, Nadine Rücker1, Curtis A Engelhart1, Meredith G Wright1, Claire Healy1, Kan Lin1, Ruojun Wang1, Sae Woong Park1, Thomas R Ioerger2, Dirk Schnappinger1, Sabine Ehrt3.   

Abstract

Chemotherapy for tuberculosis (TB) is lengthy and could benefit from synergistic adjuvant therapeutics that enhance current and novel drug regimens. To identify genetic determinants of intrinsic antibiotic susceptibility in Mycobacterium tuberculosis, we applied a chemical genetic interaction (CGI) profiling approach. We screened a saturated transposon mutant library and identified mutants that exhibit altered fitness in the presence of partially inhibitory concentrations of rifampin, ethambutol, isoniazid, vancomycin, and meropenem, antibiotics with diverse mechanisms of action. This screen identified the M. tuberculosis cell envelope to be a major determinant of antibiotic susceptibility but did not yield mutants whose increase in susceptibility was due to transposon insertions in genes encoding efflux pumps. Intrinsic antibiotic resistance determinants affecting resistance to multiple antibiotics included the peptidoglycan-arabinogalactan ligase Lcp1, the mycolic acid synthase MmaA4, the protein translocase SecA2, the mannosyltransferase PimE, the cell envelope-associated protease CaeA/Hip1, and FecB, a putative iron dicitrate-binding protein. Characterization of a deletion mutant confirmed FecB to be involved in the intrinsic resistance to every antibiotic analyzed. In contrast to its predicted function, FecB was dispensable for growth in low-iron medium and instead functioned as a critical mediator of envelope integrity.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium tuberculosis; antibiotic resistance; cell envelope; mutational studies

Mesh:

Substances:

Year:  2017        PMID: 28893793      PMCID: PMC5700314          DOI: 10.1128/AAC.01334-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  56 in total

1.  Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.

Authors:  Gail E Louw; Robin M Warren; Nicolaas C Gey van Pittius; Rosalba Leon; Adelina Jimenez; Rogelio Hernandez-Pando; Christopher R E McEvoy; Melanie Grobbelaar; Megan Murray; Paul D van Helden; Thomas C Victor
Journal:  Am J Respir Crit Care Med       Date:  2011-04-21       Impact factor: 21.405

2.  Open source clustering software.

Authors:  M J L de Hoon; S Imoto; J Nolan; S Miyano
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

3.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

4.  Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB.

Authors:  Saverio De Lorenzo; Jan Wilem Alffenaar; Giovanni Sotgiu; Rosella Centis; Lia D'Ambrosio; Simon Tiberi; Mathieu S Bolhuis; Richard van Altena; Piero Viggiani; Andrea Piana; Antonio Spanevello; Giovanni Battista Migliori
Journal:  Eur Respir J       Date:  2012-09-20       Impact factor: 16.671

5.  Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis.

Authors:  L J Piddock; K J Williams; V Ricci
Journal:  J Antimicrob Chemother       Date:  2000-02       Impact factor: 5.790

Review 6.  TB drug development: immunology at the table.

Authors:  Carl Nathan; Clifton E Barry
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

7.  FecB, a periplasmic ferric-citrate transporter from E. coli, can bind different forms of ferric-citrate as well as a wide variety of metal-free and metal-loaded tricarboxylic acids.

Authors:  Sambuddha Banerjee; Subrata Paul; Leonard T Nguyen; Byron C H Chu; Hans J Vogel
Journal:  Metallomics       Date:  2016-01       Impact factor: 4.526

8.  Mycobacterial Metabolic Syndrome: LprG and Rv1410 Regulate Triacylglyceride Levels, Growth Rate and Virulence in Mycobacterium tuberculosis.

Authors:  Amanda J Martinot; Mary Farrow; Lu Bai; Emilie Layre; Tan-Yun Cheng; Jennifer H Tsai; Jahangir Iqbal; John W Annand; Zuri A Sullivan; M Mahmood Hussain; James Sacchettini; D Branch Moody; Jessica C Seeliger; Eric J Rubin
Journal:  PLoS Pathog       Date:  2016-01-11       Impact factor: 6.823

9.  Genetic architecture of intrinsic antibiotic susceptibility.

Authors:  Hany S Girgis; Alison K Hottes; Saeed Tavazoie
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

10.  An attenuated mutant of the Rv1747 ATP-binding cassette transporter of Mycobacterium tuberculosis and a mutant of its cognate kinase, PknF, show increased expression of the efflux pump-related iniBAC operon.

Authors:  Vicky L Spivey; Rachael H Whalan; Elizabeth M A Hirst; Stephen J Smerdon; Roger S Buxton
Journal:  FEMS Microbiol Lett       Date:  2013-08-23       Impact factor: 2.742

View more
  33 in total

1.  Measuring Efflux and Permeability in Mycobacteria.

Authors:  Liliana Rodrigues; José A Aínsa; Miguel Viveiros
Journal:  Methods Mol Biol       Date:  2021

2.  A Protein Complex from Human Milk Enhances the Activity of Antibiotics and Drugs against Mycobacterium tuberculosis.

Authors:  Virginia Meikle; Ann-Kristin Mossberg; Avishek Mitra; Anders P Hakansson; Michael Niederweis
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

3.  Iron Acquisition in Mycobacterium tuberculosis.

Authors:  Alex Chao; Paul J Sieminski; Cedric P Owens; Celia W Goulding
Journal:  Chem Rev       Date:  2018-11-26       Impact factor: 60.622

Review 4.  Biology of antimicrobial resistance and approaches to combat it.

Authors:  Sarah M Schrader; Julien Vaubourgeix; Carl Nathan
Journal:  Sci Transl Med       Date:  2020-06-24       Impact factor: 17.956

5.  Analysis of Gene Essentiality from TnSeq Data Using Transit.

Authors:  Thomas R Ioerger
Journal:  Methods Mol Biol       Date:  2022

6.  Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.

Authors:  Nicholas C Poulton; Zachary A Azadian; Michael A DeJesus; Jeremy M Rock
Journal:  Antimicrob Agents Chemother       Date:  2022-08-03       Impact factor: 5.938

7.  Metabolic bifunctionality of Rv0812 couples folate and peptidoglycan biosynthesis in Mycobacterium tuberculosis.

Authors:  Katherine A Black; Lijun Duan; Lungelo Mandyoli; Bruna P Selbach; Weizhen Xu; Sabine Ehrt; James C Sacchettini; Kyu Y Rhee
Journal:  J Exp Med       Date:  2021-05-05       Impact factor: 17.579

8.  TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities.

Authors:  Allison F Carey; Jeremy M Rock; Inna V Krieger; Michael R Chase; Marta Fernandez-Suarez; Sebastien Gagneux; James C Sacchettini; Thomas R Ioerger; Sarah M Fortune
Journal:  PLoS Pathog       Date:  2018-03-05       Impact factor: 6.823

9.  Updated and standardized genome-scale reconstruction of Mycobacterium tuberculosis H37Rv, iEK1011, simulates flux states indicative of physiological conditions.

Authors:  Erol S Kavvas; Yara Seif; James T Yurkovich; Charles Norsigian; Saugat Poudel; William W Greenwald; Sankha Ghatak; Bernhard O Palsson; Jonathan M Monk
Journal:  BMC Syst Biol       Date:  2018-03-02

10.  Nonredundant functions of Mycobacterium tuberculosis chaperones promote survival under stress.

Authors:  Alexa Harnagel; Landys Lopez Quezada; Sae Woong Park; Catherine Baranowski; Karen Kieser; Xiuju Jiang; Julia Roberts; Julien Vaubourgeix; Amy Yang; Brock Nelson; Allison Fay; Eric Rubin; Sabine Ehrt; Carl Nathan; Tania J Lupoli
Journal:  Mol Microbiol       Date:  2020-11-03       Impact factor: 3.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.